Uncertainty Remains For Pharma Product Hopping Liability
By Benjamin Lajoie and Lauren Barnes (August 31, 2017, 12:48 PM EDT) -- Pharmaceutical prices continue to surge, catching the attention of patients, medical professionals and the media alike. These prices can effectively deny patients with more limited resources access to the medical treatment they need or otherwise break the bank.
While a particularly costly drug does not itself indicate legal wrongdoing, antitrust violations are sometimes to blame. For example, former hedge fund manager and founder of Turing Pharmaceuticals, Martin Shkreli, faced public outrage and later legal woes when he hiked the price of Daraprim overnight by 5,000 percent and worked to limit its generic competition.
Product hopping is different. It flies under the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!